General Principles - The rules aim to clarify the scope and procedures of the general manager's office meetings at Shandong Xinhua Medical Equipment Co., Ltd, ensuring lawful execution of responsibilities [1][2] - The general manager is responsible for implementing board resolutions and must act in the best interests of shareholders and the company [1][2] Authority of the General Manager - The general manager has the authority to oversee company operations, implement board decisions, and manage various aspects of governance, strategy, investment, asset management, capital operations, and risk control [2][3][4] - Specific powers include hosting management meetings, establishing internal management structures, and making decisions on significant investments and asset transfers [3][4][5] Meeting Procedures - The general manager's office meetings are convened bi-weekly, with provisions for urgent matters to be addressed as needed [12][16] - Meeting agendas must be prepared in advance, and relevant departments are required to submit proposals and necessary documentation for discussion [10][11][12] Decision-Making Process - Decisions are made based on thorough discussion and input from all attendees, with a focus on legal compliance and efficient operation [18][19] - In cases of disagreement, decisions may be postponed for further investigation and discussion [19][20] Responsibilities and Follow-Up - The human resources department is responsible for organizing meetings, preparing materials, and documenting decisions [15][16] - Follow-up on decisions made during meetings is mandatory, with designated departments required to report on the implementation status [27][30]

山 东 新 华 医 疗 器 械 股 份 有 限 公 司 2 0 2 4 环 境 ?社 会 和 公 司 治 理 E S G 山东新华医疗器械股份有限公司 报告 环 境、社会和公司治理(ESG)报告 地 址：山东省淄博市高新技术产业开发区新华医疗科技 园 ENVIRONMENTAL SOCIAL AND GOVERNANCE (ESG) REPORT 邮 编：255086 电子邮箱：dqgzb@shinva.com 联系电话：0533-3587734 新华医疗公众号 新华医疗红色家园 编制设计 山发海岳环境科技（山东）股份有限公司 责任专题： 新华八十一载 为健康创新界 卓越品质 服务健康 创新驱动 引领未来 以人为本 共筑美好 强本固基 行稳致远 环境、社会和公司治理(ESG)报告 山东新华医疗器械股份有限公司 | Environmental, Social and Governance Report 董事长致辞 尊敬的投资者、合作伙伴及社会各界朋友： 大家好！ 非常荣幸在此向大家呈上新华医疗2024年的ESG报告。 过去一年，新华医疗在复杂多变的市场环境中砥砺前行，始终将ESG 理念融入企业发展战略与日常运营 ...

Fundraising Overview - The company raised a total of RMB 1,283,564,291.24 through a non-public offering of 54,900,098 shares, with a net amount of RMB 1,276,238,913.79 after deducting issuance costs of RMB 7,325,377.45, all funds were received by February 14, 2023 [1][2] Fund Utilization - As of June 30, 2025, the company has utilized RMB 1,160,621,541.60 of the raised funds, with RMB 145,366,012.37 used in the current year, all allocated to fundraising projects [2][4] - The remaining balance in the fundraising account is RMB 149,471,571.45, which includes interest income after deducting bank fees and repayments of loans from the subsidiary [2][3] Fund Management - The company has established a dedicated account management system for the raised funds to ensure compliance with regulations and protect investor interests [2][3] - A tripartite supervision agreement was signed with several banks to manage the dedicated accounts for the raised funds [3] Project Financing - The company approved the use of raised funds to provide loans to its subsidiary, Xinhua Surgical Instruments Co., Ltd., for the expansion of high-end precision minimally invasive surgical instruments production, with a loan limit of RMB 208,725,900 [4] - The company has not used idle funds for temporary working capital or invested in financial products [4] Project Adjustments - The company has made adjustments to the timelines for certain fundraising projects due to delays in procurement, acceptance, and delivery, but these changes do not affect the project implementation entities or investment amounts [4][5] - The company has not changed the investment projects or transferred funds to external parties [4][5] Compliance and Disclosure - The company has complied with the relevant regulations regarding the management and use of raised funds, ensuring timely and accurate disclosures [4][5]

公司代码：600587 公司简称：新华医疗 山东新华医疗器械股份有限公司 二〇二五年八月二十九日 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人王玉全、主管会计工作负责人周娟娟及会计机构负责人（会计主管人员）姚海 云声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性陈述存在不确定性，不构成公司对投资者的实 质承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告中详细 描述可能存 ...

Core Viewpoint - The financial performance of Shandong Xinhua Medical Equipment Co., Ltd. has shown a decline in revenue and profit for the first half of 2025 compared to the previous year, indicating potential challenges in the company's operations and market conditions [1]. Financial Summary - Total assets at the end of the reporting period amounted to CNY 15.35 billion, a decrease of 1.15% from the previous year [1]. - Net assets attributable to shareholders increased to CNY 7.86 billion, reflecting a growth of 3.41% year-on-year [1]. - Operating revenue for the period was CNY 4.79 billion, down 7.64% compared to CNY 5.19 billion in the same period last year [1]. - Total profit decreased by 19.91% to CNY 454.48 million from CNY 567.47 million [1]. - Net profit attributable to shareholders fell by 20.35% to CNY 385.72 million, compared to CNY 484.26 million in the previous year [1]. - The net profit after deducting non-recurring gains and losses was CNY 242.75 million [1]. - The net cash flow from operating activities increased significantly by 76.86% to CNY 137.26 million [1]. - The weighted average return on net assets decreased by 1.51 percentage points to 4.99% [1]. - Basic and diluted earnings per share dropped by 35.35% to CNY 0.64 [1]. Shareholder Information - The total number of shareholders at the end of the reporting period was 39,279 [1]. - Major shareholders include Shandong Yiyang Health Industry Development Group Co., Ltd. with a holding of 28.91% and Shandong State-owned Assets Investment Holdings Co., Ltd. with 4.15% [2].

Group 1 - The core viewpoint of the article is that Xinhua Medical (SH 600587) held its 20th meeting of the 11th Board of Directors on August 27, 2025, where it reviewed the full and summary reports for the first half of 2025 [1] - For the year 2024, Xinhua Medical's revenue composition is as follows: medical devices accounted for 68.46%, pharmaceutical equipment for 21.66%, medical services for 8.32%, and other businesses for 1.56% [1] - As of the time of reporting, Xinhua Medical has a market capitalization of 9.9 billion yuan [1]

证券代码：600587 证券简称：新华医疗 编号：临 2025-036 山东新华医疗器械股份有限公司 第十一届董事会第二十次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 一、董事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届董事会第二十次会议于 2025 年 8 月 17 日以书面或通讯方式通知全体董事， 据此通知，会议于 2025 年 8 月 27 日在公司三楼会议室召开。会议以现场与通讯 相结合的方式召开，会议应到董事 11 名，实到 11 名，公司监事和高级管理人员 列席了会议，会议由董事长王玉全先生主持，会议程序符合《公司法》和《公司 章程》的规定。 二、董事会会议审议情况 （一）审议通过《公司 2025 年半年度报告全文及摘要》 董事会审计委员会审议通过了《2025 年半年度报告全文及摘要》。 会议审议通过公司根据《上海证券交易所股票上市规则》、上海证券交易所 关于上市公司定期报告编制的要求等其他相关法律法规及规范性法律文件编制 的《公司 2025 年半年度报告全文及摘要》。 公司 ...

Group 1 - The core viewpoint of the article is that Xinhua Medical (600587.SH) reported a decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Group 2 - The company achieved total operating revenue of 4.79 billion yuan, representing a year-on-year decrease of 7.64% [1] - The net profit attributable to shareholders of the parent company was 386 million yuan, down 20.35% year-on-year [1] - The basic earnings per share were reported at 0.64 yuan [1]

山东新华医疗器械股份有限公司 地 址：山东省淄博市高新技术产业开发区新华医疗科技园 邮 编：255086 电子邮箱：dqgzb@shinva.com 联系电话：0533-3587734 新华医疗公众号 新华医疗红色家园 山发海岳环境科技（山东）股份有限公司 编制设计 2024 环境 、社会和公司治理(ESG)报告 ENVIRONMENTAL SOCIAL AND GOVERNANCE (ESG) REPORT 山东新华医疗器械股份有限公司环境︑ 社会和公司治理ESG报告2024 品牌建设 百年匠心 目录 精准定位 战略赋能 | 责任专题： | | | | --- | --- | --- | | 新华八十一载 为健康创新界 | | 卓越品质 服务健康 | | 13 八十一载 新华风采 | 45 | 坚持质量制胜 | | 13 聚焦主业 协同发展 | 54 | 践行卓越服务 | | 17 | 58 | 保障数据安全 | | 18 | 59 | 可持续供应链 | 董事长致辞 关于本报告 走进新华医疗 未来展望 01 03 05 123 附录 125 可持续发展治理 | 21 | ESG战略 | | --- | -- ...

证券代码：600587 证券简称：新华医疗 公告编号：临2025-038 经中国证券监督管理委员会《关于核准山东新华医疗器械股份有限公司非公 开发行股票的批复》（证监许可[2022]1223 号）核准，新华医疗非公开发行人 民币普通股（A 股）54,900,098 股，募集资金总额为人民币 1,283,564,291.24 元，扣除各项不含税发行费用人民币 7,325,377.45 元后，实际募集资金净额为 人民币 1,276,238,913.79 元，上述资金已于 2023 年 2 月 14 日全部到位。天健 会计师事务所（特殊普通合伙）对公司本次非公开发行新股的资金到位情况进行 了审验，并于 2023 年 2 月 21 日出具了《验资报告》（天健验【2023】60 号）。 公司对募集资金采取了专户存储管理。 （二）募集资金使用和结余情况 截至 2025 年 6 月 30 日，公司累计使用募集资金人民币 1,160,621,541.60 元，其中：本年度使用 145,366,012.37 元，均投入募集资金项目。 截至 2025 年 6 月 30 日，公司累计使用金额人民币 1,160,621,541.60 ...